MOLN

2.5255.25%
SS

Sandip S. Kapadia

Independent Director

Mr. Sandip S. Kapadia, MBA, CPA, is Independent Director of Alentis Therapeutics AG from August 2024. He is Independent Director of Windward Bio AG from May 2026. He is Lead Independent Director of Windward Bio Group AG and has been its Independent Director since May 2026. He is Chief Financial Officer at TORL BioTherapeutics LLC since October 2026. Mr. Kapadia served as Chief Financial officer at Harmony Biosciences, LLC and served as its Chief Administrative Officer from 2023. He has life sciences industry experience across multiple therapeutic areas and has provided strategic financial oversight and guidance to companies both in the United States and Europe. He served as Executive Vice President and Chief Financial Officer at Harmony Biosciences Holdings, Inc. since March 29, 2021 until April 14, 2026 and served as its Chief Administrative Officer since September 30, 2023 until April 14, 2026. He is an Independent Director at VectivBio Holding AG since October 2020. Mr. Kapadia served as the Chief Financial Officer and Treasurer of Intercept Pharmaceuticals, Inc. since July 1, 2016 until March 26, 2021 and its Principal Accounting Officer until March 26, 2021., where he built upon the company’s key functional capabilities, developed and executed financial and capital strategies to prepare for commercial launch. Mr. Kapadia serves as Director at Molecular Partners AG since April 29, 2020. Mr. Kapadia has been an Independent Director at Passage Bio, Inc. since December 2019. Mr. Kapadia served in various leadership capacities within finance over 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the U.S. He served as the Chief Financial Officer, Head of Finance for North America and Vice President at Sandoz Inc. Mr. Kapadia joined Intercept from Sandoz, Inc., a division of Novartis AG, where he served as Vice President and Chief Financial Officer — North America from July 2014 to June 2016. From March 2012 to June 2014, Mr. Kapadia served as Vice President and Chief Financial Officer of Novartis Pharmaceuticals UK Limited. Mr. Kapadia spent the majority of his career at Novartis and Novartis affiliates in the United States, Switzerland, the Netherlands and the United Kingdom, where he held positions of varying levels of responsibility, Mr. Kapadia also served as Vice President and Chief Financial Officer of Novartis Pharmaceuticals B.V. located in the Netherlands from 2009 through 2012. Prior to that, he served as Head of finance — oncology business unit for both Novartis Pharmaceuticals A.G. and Novartis Pharmaceuticals Corporation. Mr. Kapadia is currently a director of Vectiv Bio Holding AG since December 2020 and previously of Therachon AG. Mr. Kapadia earned his Bachelor of Science degree in accounting from Montclair State University, an MBA from Rutgers Graduate School of Management and is a certified public accountant.

Positions